Aims: To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT)] vs. a reference regimen (12-month aspirin monotherapy following 12-month DAPT) after complex percutaneous coronary intervention (PCI). Methods and results In the present post hoc analysis of the Global Leaders trial, the primary endpoint [composite of all-cause death or new Q-wave myocardial infarction (MI)] at 2 years was assessed in patients with complex PCI, which includes at least one of the following characteristics: multivessel PCI, >= 3 stents implanted, >= 3 lesions treated, bifurcation PCI with >= 2 stents, or total stent length >60 mm. In addition, patient-oriented composite endpoint (POCE) ...
Objectives: The aim of this study was to compare ticagrelor monotherapy with dual-antiplatelet thera...
BACKGROUND Data on optimal antiplatelet treatment regimens in patients who undergo multivessel pe...
BACKGROUND: We hypothesised that ticagrelor, in combination with aspirin for 1 month, followed by ti...
AIMS To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy followi...
Aims: The aim of this study was to evaluate the impact of 23-month ticagrelor monotherapy following ...
Aims: The aim of this study was to evaluate the impact of 23-month ticagrelor monotherapy following ...
Background: The aim of this study was to investigate the impact of ticagrelor monotherapy following ...
BACKGROUND The aim of this study was to investigate the impact of ticagrelor monotherapy followin...
Background: The optimal antiplatelet strategy in the second year after percutaneous coronary interve...
AIMS: The aim of this study was to evaluate the impact of a novel antiplatelet regimen in patients w...
Background/Introduction: data on the efficacy and safety of different antiplatelet regimens are li...
BACKGROUND The optimal antiplatelet strategy in the second year after percutaneous coronary inter...
Aims: Optimal timing and strategy of antiplatelet monotherapy after dual-antiplatelet therapy (DAPT)...
Background: The GLOBAL LEADERS (GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platele...
BACKGROUND The GLOBAL LEADERS (GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-plate...
Objectives: The aim of this study was to compare ticagrelor monotherapy with dual-antiplatelet thera...
BACKGROUND Data on optimal antiplatelet treatment regimens in patients who undergo multivessel pe...
BACKGROUND: We hypothesised that ticagrelor, in combination with aspirin for 1 month, followed by ti...
AIMS To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy followi...
Aims: The aim of this study was to evaluate the impact of 23-month ticagrelor monotherapy following ...
Aims: The aim of this study was to evaluate the impact of 23-month ticagrelor monotherapy following ...
Background: The aim of this study was to investigate the impact of ticagrelor monotherapy following ...
BACKGROUND The aim of this study was to investigate the impact of ticagrelor monotherapy followin...
Background: The optimal antiplatelet strategy in the second year after percutaneous coronary interve...
AIMS: The aim of this study was to evaluate the impact of a novel antiplatelet regimen in patients w...
Background/Introduction: data on the efficacy and safety of different antiplatelet regimens are li...
BACKGROUND The optimal antiplatelet strategy in the second year after percutaneous coronary inter...
Aims: Optimal timing and strategy of antiplatelet monotherapy after dual-antiplatelet therapy (DAPT)...
Background: The GLOBAL LEADERS (GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platele...
BACKGROUND The GLOBAL LEADERS (GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-plate...
Objectives: The aim of this study was to compare ticagrelor monotherapy with dual-antiplatelet thera...
BACKGROUND Data on optimal antiplatelet treatment regimens in patients who undergo multivessel pe...
BACKGROUND: We hypothesised that ticagrelor, in combination with aspirin for 1 month, followed by ti...